<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04026685</url>
  </required_header>
  <id_info>
    <org_study_id>2019-00866; qu18Buddeberg</org_study_id>
    <nct_id>NCT04026685</nct_id>
  </id_info>
  <brief_title>Maternal Haemodynamic Changes After Crystalloid Co-loading and Phenylephrine Versus Phenylephrine Alone During Spinal Anaesthesia for Elective Caesarean Delivery</brief_title>
  <acronym>NICOM-USB</acronym>
  <official_title>Maternal Haemodynamic Changes After Crystalloid Co-loading and Phenylephrine Versus Phenylephrine Alone During Spinal Anaesthesia for Elective Caesarean Delivery: a Double-blind, Randomised Controlled Trial Using the Non Invasive Cardiac Output Monitor StarlingTM SV.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spinal anaesthesia is the anaesthetic technique of choice for elective caesarean delivery.&#xD;
      Hypotension, a result of the decrease in systemic vascular resistance caused by spinal&#xD;
      anaesthesia, is a frequent complication occurring in up to 80%. This study is to investigate&#xD;
      fluid loading plus vasopressors to vasopressors alone to maintain stable maternal&#xD;
      haemodynamics in elective caesarean delivery. The effect of the two methods (continuous&#xD;
      prophylactic phenylephrine infusion with and without crystalloid co-loading) on maternal&#xD;
      haemodynamics will be compared using the Starling SV Monitor. The Starling SV device is a non&#xD;
      invasive cardiac output monitor (NICOM) which is certified and validated for the use in&#xD;
      pregnancy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 9, 2020</start_date>
  <completion_date type="Actual">February 5, 2021</completion_date>
  <primary_completion_date type="Actual">February 5, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double-blind, randomised controlled non-inferiority trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Investigator and participant cannot see to which study group the participant belongs. The person performing randomisation and fluid application will not be involved in the data collection and Analysis.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in maternal cardiac output (CO)</measure>
    <time_frame>measured every minute after induction of spinal anaesthesia (=baseline) until 5 minutes after cord clamping</time_frame>
    <description>CO measured by area under the curve (AUC) (L/min.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in maternal heart rate</measure>
    <time_frame>measured every minute after induction of spinal anaesthesia (=baseline) until 5 minutes after cord clamping</time_frame>
    <description>Change in maternal heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in maternal diastolic and systolic blood pressure</measure>
    <time_frame>measured every minute after induction of spinal anaesthesia (=baseline) until 5 minutes after cord clamping</time_frame>
    <description>Change in maternal diastolic and systolic blood pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of maternal nausea</measure>
    <time_frame>measured every minute after induction of spinal anaesthesia (=baseline) until 5 minutes after cord clamping</time_frame>
    <description>incidence of maternal Nausea (number)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Apgar scores</measure>
    <time_frame>at 1 and 5 minutes after delivery</time_frame>
    <description>The Apgar score is determined by evaluating the newborn baby on five simple criteria on a scale from zero to two, then summing up the five values thus obtained. The resulting Apgar score ranges from zero to 10. The five criteria are summarized using words chosen to form a backronym (Appearance, Pulse, Grimace, Activity, Respiration).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in umbilical cord pH</measure>
    <time_frame>at 1 and 5 minutes after delivery</time_frame>
    <description>Change in umbilical cord pH</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Maternal Haemodynamic Stability</condition>
  <arm_group>
    <arm_group_label>Phenylephrine infusion only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phenylephrine infusion only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenylephrine infusion and Ringer-Acetate bolus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phenylephrine infusion and Ringer-Acetate bolus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine infusion</intervention_name>
    <description>continuous phenylephrine infusion started at a rate of 25mcg/min and titrated according to blood pressure</description>
    <arm_group_label>Phenylephrine infusion only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine infusion and Ringer-Acetate bolus</intervention_name>
    <description>continuous phenylephrine infusion started at a rate of 25mcg/min and titrated according to blood pressure plus crystalloid Ringer-Acetate co-loading bolus of 1000 mL</description>
    <arm_group_label>Phenylephrine infusion and Ringer-Acetate bolus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to give informed consent&#xD;
&#xD;
          -  Term uncomplicated singleton pregnancy&#xD;
&#xD;
          -  Undergoing elective caesarean section under spinal anaesthesia&#xD;
&#xD;
          -  Weight: 50-100kg&#xD;
&#xD;
          -  Height: 150-180cm&#xD;
&#xD;
          -  Healthy term fetus&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
&#xD;
          -  Multiple pregnancy&#xD;
&#xD;
          -  Clinically significant concomitant disease states (e.g. hypertension, cardiac disease,&#xD;
             severe asthma requiring regular medication, comorbidities affecting the autonomous&#xD;
             nervous system, renal disease)&#xD;
&#xD;
          -  On any cardiovascular medication&#xD;
&#xD;
          -  Complications of pregnancy (e.g. preeclampsia, intrauterine growth restriction, fetal&#xD;
             malformations)&#xD;
&#xD;
          -  Known or suspected non-compliance, drug or alcohol abuse&#xD;
&#xD;
          -  Inability to follow the procedures of the study, e.g. due to language problems,&#xD;
             psychological disorders, dementia of the participant,&#xD;
&#xD;
          -  Participation in another study with investigational drug within the 30 days preceding&#xD;
             and during the present study,&#xD;
&#xD;
          -  Previous enrolment into the current study,&#xD;
&#xD;
          -  Enrolment of the investigator, his/her family members, employees and other dependent&#xD;
             persons&#xD;
&#xD;
          -  Any fetal pathology (e.g. fetal malformations, rupture of membranes before caesarean&#xD;
             section, oligohydramnios, polyhydramnios, suspected chorioamnionitis)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bigna Buddeberg, Dr. med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anaesthesiology, University Hospital of Basel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Anaesthesiology, University Hospital of Basel (USB)</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2019</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>caesarean delivery</keyword>
  <keyword>phenylephrine</keyword>
  <keyword>spinal anaesthesia</keyword>
  <keyword>vasopressor administration</keyword>
  <keyword>pregnancy</keyword>
  <keyword>non invasive cardiac output (CO) monitoring (NICOM)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

